Axovant's Much-Hyped Alzheimer's Drug Flunks Phase III Test

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x430-axovant-david-hung.jpg" NAME"Axovant's Much-Hyped Alzheimer's Drug Flunks Phase III Test" ALT"Axovant's Much-Hyped Alzheimer's Drug Flunks Phase III Test"September 26, 2017By Mark Terry, BioSpace.com Breaking News Staff... Source: BioSpace

Continue ReadingAxovant's Much-Hyped Alzheimer's Drug Flunks Phase III Test

Stock Plummets as Genocea Axes 40% of Jobs, Shifts R&D Focus in Restructuring

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x450-stocks-down2.jpg" NAME"Stock Plummets as Genocea Axes 40% of Jobs, Shifts R&D Focus in Restructuring" ALT"Stock Plummets as Genocea Axes 40% of Jobs, Shifts R&D Focus in Restructuring"September 26, 2017By…

Continue ReadingStock Plummets as Genocea Axes 40% of Jobs, Shifts R&D Focus in Restructuring

26-Employee Cue BioPharma Seeks $40 Million IPO Eight Months After Emerging From Stealth Mode

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x450-stocks.jpg" NAME"26-Employee Cue BioPharma Seeks $40 Million IPO Eight Months After Emerging From Stealth Mode" ALT"26-Employee Cue BioPharma Seeks $40 Million IPO Eight Months After Emerging From Stealth Mode"September…

Continue Reading26-Employee Cue BioPharma Seeks $40 Million IPO Eight Months After Emerging From Stealth Mode